Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIKE trial of infliximab for artificial stone-associated complicated silicosis
ACTRN12625000499482Phase 2Not yet recruiting
- Sponsor
- Alfred Health
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of infliximab in silicosis, sponsored by Alfred Health. Primary endpoints: Change in lung function parameters, Change in inflammatory activity and 1 more. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
infliximab
03
Conditions
silicosis
Beyond the preview
Go deeper on ACTRN12625000499482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000499482.